Eligible participants will receive daily treatment with 1500 mg voxelotor or matching placebo for 12 weeks. During screening and at the end of 12 weeks, participants will undergo an MRI for evaluation of cerebral blood flow and oxygen extraction fraction.
This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the impact of voxelotor treatment on cerebral blood flow (CBF) in adult and adolescent participants (12-30 years of age) with sickle cell disease (SCD).